MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders

Not Applicable

Completed

Conditions: Pervasive Developmental Disorders
ASD
Autism Spectrum Disorders
PDD

Interventions: Drug: Intranasal Oxytocin

First Posted Date: 2013-08-29

Last Posted Date: 2024-07-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 8

Registration Number: NCT01931033

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

Not Applicable

Completed

Conditions: HIV Disease

Interventions: Drug: Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)

First Posted Date: 2013-08-28

Last Posted Date: 2017-07-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 10

Registration Number: NCT01929759

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study

Not Applicable

Completed

Conditions: Papillary Carcinoma of Thyroid Gland
Metastatic Medullary Thyroid Cancer
Follicular Thyroid Cancer Lymph Node Metastasis

Interventions: Drug: Ferumoxytol
Device: Nanoparticle MRI

First Posted Date: 2013-08-23

Last Posted Date: 2017-06-06

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 12

Registration Number: NCT01927887

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

Phase 2

Completed

Conditions: Treatment Resistant Depression

Interventions: Drug: Placebo Midazolam
Drug: Ketamine

First Posted Date: 2013-08-12

Last Posted Date: 2018-06-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 99

Registration Number: NCT01920555

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

and more 3 locations

Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study

Phase 4

Withdrawn

Conditions: Coronary Artery Disease
Acute Coronary Syndrome

Interventions: Drug: Ticagrelor- Delayed Administration
Drug: Ticagrelor- Immediate Administration
Procedure: Optical Coherence Tomography

First Posted Date: 2013-08-06

Last Posted Date: 2014-05-26

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT01916902

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder

Phase 2

Completed

Conditions: Autism Spectrum Disorders

Interventions: Drug: placebo drug
Behavioral: Social Skills focused CBT
Behavioral: Stress management/relaxation training
Drug: Oxytocin

First Posted Date: 2013-08-02

Last Posted Date: 2020-01-27

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 92

Registration Number: NCT01914939

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts Institute of Technology Martinos Imaging Center, Cambridge, Massachusetts, United States

Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum

Phase 1

Completed

Conditions: Clostridium Difficile Infection

Interventions: Drug: Fecal Microbiota Transplant

First Posted Date: 2013-08-02

Last Posted Date: 2016-07-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT01914731

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

Phase 2

Terminated

Conditions: Treatment Resistant Depression

Interventions: Drug: CERC-501
Drug: Placebo

First Posted Date: 2013-08-01

Last Posted Date: 2017-07-02

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 8

Registration Number: NCT01913535

Locations: 🇺🇸
University of Kansas, Wichita, Kansas, United States
🇺🇸
Rush University, Chicago, Illinois, United States
🇺🇸
Temple University, Philadelphia, Pennsylvania, United States

and more 1 locations

Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury

Not Applicable

Active, not recruiting

Conditions: Chronic Radiation Dermatitis

Interventions: Device: Fractional CO2 laser treatment
Other: No treatment

First Posted Date: 2013-07-30

Last Posted Date: 2023-11-02

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 12

Registration Number: NCT01910818

Locations: 🇺🇸
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, United States

Longitudinal Study of Outcomes Measures in ALS Trials

Completed

Conditions: Amyotrophic Lateral Sclerosis

First Posted Date: 2013-07-30

Last Posted Date: 2017-03-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 100

Registration Number: NCT01911130

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy